Frequency and characteristics of dysautonomic symptoms in multiple sclerosis: a cross-sectional double-center study with the validated Italian version of the Composite Autonomic Symptom Score-31.
COMPASS-31
Disease activity
Dysautonomia
EDSS
Multiple sclerosis
Progression
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
18
02
2020
accepted:
19
07
2020
pubmed:
11
8
2020
medline:
15
5
2021
entrez:
11
8
2020
Statut:
ppublish
Résumé
Dysautonomic symptoms (DS) are frequent but often underrecognized in multiple sclerosis (MS) patients, despite the relevant impact on quality of life and physical performance. To assess frequency and characteristics of DS in our MS population compared with healthy controls (HC). To investigate the relationship between DS and disease characteristics (MS subtype, disease duration, Expanded Disability Status Scale (EDSS), clinical and/or radiological activity, disability progression). Cross-sectional study includes 324 MS patients (mean age 44.9 ± 10.7 years; 66% female) and 190 HC (mean age 40.60 ± 12.83 years; 63% female). DS were assessed using the Italian validated version of the Composite Autonomic Symptom Score-31 (COMPASS-31). Possible confounding factors were considered. More than 94% of enrolled MS patients reported alterations in ≥ 2 domains of the COMPASS-31 scale (score > 0) and significantly higher COMPASS-31 total and single domain median scores compared with HC, independently from possible confounding factors (orthostatic intolerance: p = 0.001; vasomotor: p = 0.017; secretomotor: p = 0.040; gastrointestinal: p = 0.047; bladder: p < 0.001; pupillomotor: p < 0.001; COMPASS-31 total score: p < 0.001). COMPASS-31 total, secretomotor, gastrointestinal, and bladder domain scores showed weak to moderate correlation with disease duration (Rho = 0.19, p < 0.001; Rho = 0.18, p = 0.01; Rho = 0.25, p = 0.030; Rho = 0.28, p < 0.001, respectively). A moderate correlation between EDSS score, COMPASS-31 total, and bladder domain scores (Rho = 0.32, p < 0.001 and Rho = 0.48, p < 0.001, respectively) was observed. Progressive subtypes showed higher COMPASS-31 total (p = 0.025), gastrointestinal (p = 0.07), and bladder (p < 0.001) domain scores vs relapsing-remitting patients. Our findings confirm that MS-related DS are frequent and tend to increase paralleling disease duration and clinical worsening, reaching the highest clinical impact in progressive subtypes.
Sections du résumé
BACKGROUND
BACKGROUND
Dysautonomic symptoms (DS) are frequent but often underrecognized in multiple sclerosis (MS) patients, despite the relevant impact on quality of life and physical performance.
OBJECTIVES
OBJECTIVE
To assess frequency and characteristics of DS in our MS population compared with healthy controls (HC). To investigate the relationship between DS and disease characteristics (MS subtype, disease duration, Expanded Disability Status Scale (EDSS), clinical and/or radiological activity, disability progression).
PATIENTS AND METHODS
METHODS
Cross-sectional study includes 324 MS patients (mean age 44.9 ± 10.7 years; 66% female) and 190 HC (mean age 40.60 ± 12.83 years; 63% female). DS were assessed using the Italian validated version of the Composite Autonomic Symptom Score-31 (COMPASS-31). Possible confounding factors were considered.
RESULTS
RESULTS
More than 94% of enrolled MS patients reported alterations in ≥ 2 domains of the COMPASS-31 scale (score > 0) and significantly higher COMPASS-31 total and single domain median scores compared with HC, independently from possible confounding factors (orthostatic intolerance: p = 0.001; vasomotor: p = 0.017; secretomotor: p = 0.040; gastrointestinal: p = 0.047; bladder: p < 0.001; pupillomotor: p < 0.001; COMPASS-31 total score: p < 0.001). COMPASS-31 total, secretomotor, gastrointestinal, and bladder domain scores showed weak to moderate correlation with disease duration (Rho = 0.19, p < 0.001; Rho = 0.18, p = 0.01; Rho = 0.25, p = 0.030; Rho = 0.28, p < 0.001, respectively). A moderate correlation between EDSS score, COMPASS-31 total, and bladder domain scores (Rho = 0.32, p < 0.001 and Rho = 0.48, p < 0.001, respectively) was observed. Progressive subtypes showed higher COMPASS-31 total (p = 0.025), gastrointestinal (p = 0.07), and bladder (p < 0.001) domain scores vs relapsing-remitting patients.
CONCLUSIONS
CONCLUSIONS
Our findings confirm that MS-related DS are frequent and tend to increase paralleling disease duration and clinical worsening, reaching the highest clinical impact in progressive subtypes.
Identifiants
pubmed: 32776288
doi: 10.1007/s10072-020-04620-1
pii: 10.1007/s10072-020-04620-1
pmc: PMC7955976
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1395-1403Références
Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ (2014) Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 83:1022–1024
doi: 10.1212/WNL.0000000000000768
Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221–1231
doi: 10.1016/S0140-6736(02)08220-X
Haensch CA, Jörg J (2006) Autonomic dysfunction in multiple sclerosis. J Neurol. 253(Suppl 1):I3–I9 Review
doi: 10.1007/s00415-006-1102-2
Vita G, Fazio MC, Milone S, et al. (1993) Cardiovascular autonomic dysfunction in multiple sclerosis is likely related to brainstem lesions. J Neurol Sci 1993;120(1):82–86
Racosta JM, Kimpinski K (2016) Autonomic dysfunction, immune regulation, and multiple sclerosis. Clin Auton Res 26:23–31
doi: 10.1007/s10286-015-0325-7
Flachenecker P, Reiners K, Krauser M, Wolf A, Toyka KV (2001) Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler 7:327–334
doi: 10.1177/135245850100700509
Sletten DM, Suarez GA, Low PA et al (2012) COMPASS 31: a refined and abbreviated composite autonomic symptom score. Mayo ClinProc. 87(12):1196–1201
doi: 10.1016/j.mayocp.2012.10.013
Drulović J, Gavrilović A, Crnošija L et al (2017 Oct 31) Validation and cross-cultural adaptation of the COMPASS-31 in Croatian and Serbian patients with multiple sclerosis. Croat Med J 58(5):342–348
doi: 10.3325/cmj.2017.58.
Pierangeli G, Turrini A, Giannini G, del Sorbo F, Calandra-Buonaura G, Guaraldi P, Bacchi Reggiani ML, Cortelli P (2015) Translation and linguistic validation of the Composite Autonomic Symptom Score COMPASS 31. Neurol Sci 36(10):1897–1902
doi: 10.1007/s10072-015-2278-y
Cuschieri S (2019) The STROBE guidelines. Saudi J Anaesth 13(Suppl 1):S31–S34
doi: 10.4103/sja.SJA_543_18
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173
doi: 10.1016/S1474-4422(17)30470-2
Middlekauff HR, Park J, Moheimani RS (2014) Adverse effects of cigarette and noncigarette smoke exposure on the autonomic nervous system: mechanisms and implications for cardiovascular risk. J Am Coll Cardiol. 64(16):1740–1750
doi: 10.1016/j.jacc.2014.06.1201
Ferraro D, Camera V, Baldi E, Vacchiano V, Curti E, Guareschi A, Malagù S, Montepietra S, Strumia S, Santangelo M, Caniatti L, Foschi M, Lugaresi A, Granella F, Pesci I, Motti L, Neri W, Immovilli P, Montanari E, Vitetta F, Simone AM, Sola P (2018) First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence. Curr Med Res Opin 34(10):1803–1807
doi: 10.1080/03007995.2018.1451311
Videira G, Castro P, Vieira B, Filipe JP, Santos R, Azevedo E, Sá MJ, Abreu P (2016) Autonomic dysfunction in multiple sclerosis is better detected by heart rate variability and is not correlated with central autonomic network damage. J Neurol Sci 367:133–137
doi: 10.1016/j.jns.2016.05.049
Vieira B, Costa A, Videira G, Sá MJ, Abreu P (2015) Prevalence of autonomic dysfunction in patients with multiple sclerosis. Acta Medica Port 28(1):51–55
doi: 10.20344/amp.5562
Hinds JP, Eidelman BH, Wald A (1990) Prevalence of bowel dysfunction in multiple sclerosis. A population survey. Gastroenterology. 98(6):1538–1542
doi: 10.1016/0016-5085(90)91087-M
Chia YW, Gill KP, Jameson JS et al Paradoxical puborectalis contraction is a feature of constipation in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 60(1):31–35
el-Maghraby TA, Shalaby NM, Al-Tawdy MH et al (2005) Gastric motility dysfunction in patients with multiple sclerosis assessed by gastric emptying scintigraphy. Can J Gastroenterol 19(3):141–145
doi: 10.1155/2005/103615
Saari A, Tolonen U, Pääkkö E et al (2009) Sweating impairment in patients with multiple sclerosis. Acta Neurol Scand. 120(5):358–363
doi: 10.1111/j.1600-0404.2009.01164.x
Adamec I, Bach I, Barušić AK, Mišmaš A, Habek M (2013) Assessment of prevalence and pathological response to orthostatic provocation in patients with multiple sclerosis. J Neurol Sci 324(1–2):80–83
doi: 10.1016/j.jns.2012.10.006
De Seze J, Arndt C, Stojkovic T et al (2001) Pupillary disturbances in multiple sclerosis: correlation with MRI findings. J Neurol Sci 188(1–2):37–41
doi: 10.1016/S0022-510X(01)00540-8
Crnošija L, Krbot Skorić M, Andabaka M, Junaković A, Martinović V, Ivanović J, Mesaroš Š, Pekmezović T, Drulović J, Habek M (2020) Autonomic dysfunction in people with neuromyelitis optica spectrum disorders. Mult Scler 26(6):688–695
doi: 10.1177/1352458519837703
Singer W, Sletten D, Mandrekar J et al (2013) Validation of a refined and abbreviated composite autonomic symptom score. Neurology 80(S37):001
Gunal DI, Afsar N, Tanridag T, Aktan S (2002) Autonomic dysfunction in multiple sclerosis: correlation with disease-related parameters. Eur Neurol 48(1):1–5
doi: 10.1159/000064949
Cortez MM, Nagi Reddy SK, Goodman B et al (2015) Autonomic symptom burden is associated with MS-related fatigue and quality of life. Mult Scler Relat Disord 4(3):258–263
doi: 10.1016/j.msard.2015.03.007
Adamec I, Crnošija L, Junaković A, Krbot Skorić M, Habek M (2018) Progressive multiple sclerosis patients have a higher burden of autonomic dysfunction compared to relapsing remitting phenotype. Clin Neurophysiol 129(8):1588–1594
doi: 10.1016/j.clinph.2018.05.009
Krbot Skorić M, Crnošija L, Gabelić T et al (2019) Autonomic symptom burden can predict disease activity in early multiple sclerosis. Mult Scler Relat Disord. 28:250–255
doi: 10.1016/j.msard.2019.01.005